175 related articles for article (PubMed ID: 24813658)
1. Epigenetic-related gene expression profile in medullary thyroid cancer revealed the overexpression of the histone methyltransferases EZH2 and SMYD3 in aggressive tumours.
Sponziello M; Durante C; Boichard A; Dima M; Puppin C; Verrienti A; Tamburrano G; Di Rocco G; Redler A; Lacroix L; Bidart JM; Schlumberger M; Damante G; Russo D; Filetti S
Mol Cell Endocrinol; 2014 Jul; 392(1-2):8-13. PubMed ID: 24813658
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic regulation of cell adhesion and communication by enhancer of zeste homolog 2 in human endothelial cells.
Dreger H; Ludwig A; Weller A; Stangl V; Baumann G; Meiners S; Stangl K
Hypertension; 2012 Nov; 60(5):1176-83. PubMed ID: 22966008
[TBL] [Abstract][Full Text] [Related]
3. Role of STAT3 and vitamin D receptor in EZH2-mediated invasion of human colorectal cancer.
Lin YW; Ren LL; Xiong H; Du W; Yu YN; Sun TT; Weng YR; Wang ZH; Wang JL; Wang YC; Cui Y; Sun DF; Han ZG; Shen N; Zou W; Xu J; Chen HY; Cao W; Hong J; Fang JY
J Pathol; 2013 Jul; 230(3):277-90. PubMed ID: 23424038
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic Control of Skeletal Development by the Histone Methyltransferase Ezh2.
Dudakovic A; Camilleri ET; Xu F; Riester SM; McGee-Lawrence ME; Bradley EW; Paradise CR; Lewallen EA; Thaler R; Deyle DR; Larson AN; Lewallen DG; Dietz AB; Stein GS; Montecino MA; Westendorf JJ; van Wijnen AJ
J Biol Chem; 2015 Nov; 290(46):27604-17. PubMed ID: 26424790
[TBL] [Abstract][Full Text] [Related]
5. Correlations of
Ma SJ; Liu YM; Zhang YL; Chen MW; Cao W
Biosci Rep; 2018 Feb; 38(1):. PubMed ID: 29089464
[TBL] [Abstract][Full Text] [Related]
6. Aggressive inherited and sporadic medullary thyroid carcinomas display similar oncogenic pathways.
Ameur N; Lacroix L; Roucan S; Roux V; Broutin S; Talbot M; Dupuy C; Caillou B; Schlumberger M; Bidart JM
Endocr Relat Cancer; 2009 Dec; 16(4):1261-72. PubMed ID: 19675075
[TBL] [Abstract][Full Text] [Related]
7. Enhancer of zeste homolog 2 expression is associated with metastasis and adverse clinical outcome in clear cell renal cell carcinoma: a comparative study and review of the literature.
Xu B; Abourbih S; Sircar K; Kassouf W; Mansure JJ; Aprikian A; Tanguay S; Brimo F
Arch Pathol Lab Med; 2013 Oct; 137(10):1326-36. PubMed ID: 24079759
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic reprogramming in solid tumors: therapeutic implications of EZH2 gain-of-function mutations.
Barsotti AM; Ryskin M; Rollins RA
Epigenomics; 2015 Aug; 7(5):687-90. PubMed ID: 26317265
[No Abstract] [Full Text] [Related]
9. EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity.
Yan J; Ng SB; Tay JL; Lin B; Koh TL; Tan J; Selvarajan V; Liu SC; Bi C; Wang S; Choo SN; Shimizu N; Huang G; Yu Q; Chng WJ
Blood; 2013 May; 121(22):4512-20. PubMed ID: 23529930
[TBL] [Abstract][Full Text] [Related]
10. Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series.
Ciampi R; Mian C; Fugazzola L; Cosci B; Romei C; Barollo S; Cirello V; Bottici V; Marconcini G; Rosa PM; Borrello MG; Basolo F; Ugolini C; Materazzi G; Pinchera A; Elisei R
Thyroid; 2013 Jan; 23(1):50-7. PubMed ID: 23240926
[TBL] [Abstract][Full Text] [Related]
11. The PDCD4/miR-21 pathway in medullary thyroid carcinoma.
Pennelli G; Galuppini F; Barollo S; Cavedon E; Bertazza L; Fassan M; Guzzardo V; Pelizzo MR; Rugge M; Mian C
Hum Pathol; 2015 Jan; 46(1):50-7. PubMed ID: 25316501
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring.
Xu F; Li X; Wu L; Zhang Q; Yang R; Yang Y; Zhang Z; He Q; Chang C
Ann Hematol; 2011 Jun; 90(6):643-53. PubMed ID: 21125401
[TBL] [Abstract][Full Text] [Related]
13. Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification.
Mian C; Pennelli G; Barollo S; Cavedon E; Nacamulli D; Vianello F; Negro I; Pozza G; Boschin IM; Pelizzo MR; Rugge M; Mantero F; Girelli ME; Opocher G
Eur J Endocrinol; 2011 Jun; 164(6):971-6. PubMed ID: 21422198
[TBL] [Abstract][Full Text] [Related]
14. Roles of the EZH2 histone methyltransferase in cancer epigenetics.
Simon JA; Lange CA
Mutat Res; 2008 Dec; 647(1-2):21-9. PubMed ID: 18723033
[TBL] [Abstract][Full Text] [Related]
15. mTOR activation in medullary thyroid carcinoma with RAS mutation.
Lyra J; Vinagre J; Batista R; Pinto V; Prazeres H; Rodrigues F; Eloy C; Sobrinho-Simões M; Soares P
Eur J Endocrinol; 2014 Nov; 171(5):633-40. PubMed ID: 25163725
[TBL] [Abstract][Full Text] [Related]
16. EZH2 and KDM6A act as an epigenetic switch to regulate mesenchymal stem cell lineage specification.
Hemming S; Cakouros D; Isenmann S; Cooper L; Menicanin D; Zannettino A; Gronthos S
Stem Cells; 2014 Mar; 32(3):802-15. PubMed ID: 24123378
[TBL] [Abstract][Full Text] [Related]
17. The polycomb group protein enhancer of zeste 2 is a novel therapeutic target for cervical cancer.
Ding M; Zhang H; Li Z; Wang C; Chen J; Shi L; Xu D; Gao Y
Clin Exp Pharmacol Physiol; 2015 May; 42(5):458-64. PubMed ID: 25739318
[TBL] [Abstract][Full Text] [Related]
18. Aberrant expression of EZH2 is associated with pathological findings and P53 alteration.
Shiogama S; Yoshiba S; Soga D; Motohashi H; Shintani S
Anticancer Res; 2013 Oct; 33(10):4309-17. PubMed ID: 24122997
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic reprogramming by tumor-derived EZH2 gain-of-function mutations promotes aggressive 3D cell morphologies and enhances melanoma tumor growth.
Barsotti AM; Ryskin M; Zhong W; Zhang WG; Giannakou A; Loreth C; Diesl V; Follettie M; Golas J; Lee M; Nichols T; Fan C; Li G; Dann S; Fantin VR; Arndt K; Verhelle D; Rollins RA
Oncotarget; 2015 Feb; 6(5):2928-38. PubMed ID: 25671303
[TBL] [Abstract][Full Text] [Related]
20. Expression of DNA methyltransferases 1 and 3B correlates with EZH2 and this 3-marker epigenetic signature predicts outcome in glioblastomas.
Purkait S; Sharma V; Kumar A; Pathak P; Mallick S; Jha P; Sharma MC; Suri V; Julka PK; Suri A; Sharma BS; Sarkar C
Exp Mol Pathol; 2016 Apr; 100(2):312-20. PubMed ID: 26892683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
